行情

LCTX

LCTX

Lineage Cell The
AMEX

实时行情|Nasdaq Last Sale

1.250
+0.030
+2.46%
盘后: 1.260 +0.01 +0.80% 19:16 05/26 EDT
开盘
1.210
昨收
1.220
最高
1.260
最低
1.210
成交量
42.18万
成交额
0
52周最高
3.000
52周最低
1.100
市值
2.12亿
市盈率(TTM)
-4.3148
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解LCTX最新的财务预测,通过LCTX每股收益,每股净资产,每股现金流等数据分析Lineage Cell The近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
83.33%买入
16.67%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测LCTX价格均价为6.40,最高价位8.00,最低价为5.00。
最高8.00
均价6.40
最低5.00
现价1.250
EPS
实际EPS
预期EPS
-0.14-0.10-0.07-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 118
机构持股: 6,639.54万
持股比例: 39.12%
总股本: 1.70亿
类型机构数股数
增持
29
92.00万
建仓
11
162.96万
减持
26
98.89万
平仓
19
128.65万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.99%
制药与医学研究
+0.43%
高管信息
Chairman/Director
Alfred Kingsley
Chief Executive Officer/Director
Brian Culley
Chief Financial Officer
Kevin Cook
Finance Director/Controller
Alexandra Hernandez
Senior Vice President
Gary Hogge
General Counsel/Secretary
George Samuel
Independent Director
Dipti Amin
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Anula Jayasuriya
Independent Director
Michael Mulroy
Independent Director
Angus Russell
暂无数据
暂无数据
LCTX 简况
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The Company has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

微牛提供Lineage Cell Therapeutics Inc(AMEX-LCTX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的LCTX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LCTX股票基本功能。